Trial Profile
A Phase I/II, Randomised, Double-Blind, Placebo Controlled Study, Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Single and Multiple Intravenous Doses of ALX-0061 in Patients With RA.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Vobarilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Proof of concept
- Sponsors Ablynx
- 15 Jun 2013 24-Week results presented at the 14th Annual Congress of the European League Against Rheumatism.
- 12 Jun 2013 24-week final analysis of the phase II part of this trial will be presented at the 2013 Annual European Congress of Rheumatology (EULAR), according to an Ablynx media release.
- 27 Feb 2013 Status changed from active, no longer recruiting to completed as reported in an Abbvie media release.